<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40864451</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2380-6591</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>27</Day></PubDate></JournalIssue><Title>JAMA cardiology</Title><ISOAbbreviation>JAMA Cardiol</ISOAbbreviation></Journal><ArticleTitle>Clinical Outcomes With Personalized Accelerated Physiologic Pacing in Heart Failure With Preserved Ejection Fraction: Follow-up of the myPACE Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e252827</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamacardio.2025.2827</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="UNASSIGNED">Patients with heart failure with preserved ejection fraction (HFpEF) and physiologic pacemakers may benefit from pacing rates above the standard 60 beats per minute (bpm).</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To compare adverse event accrual between personalized accelerated pacing and usual care in HFpEF.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="UNASSIGNED">This was an observational extension of the myPACE randomized clinical trial with up to 4 years of follow-up in 100 patients with stage B or C HFpEF and preexisting physiologic pacemakers treated at the University of Vermont Medical Center. The myPACE study was conducted from June 2019 to December 2021; follow-up for this report was concluded in June 2023.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="UNASSIGNED">Participants in the original myPACE trial were randomly assigned to either personalized accelerated pacing (myPACE) or 60 bpm (usual care).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="UNASSIGNED">The primary outcome was the accrual of first and recurrent adverse clinical events during the open-label follow-up phase-including urgent visits or hospitalizations for heart failure or atrial fibrillation, myocardial infarction, stroke, or death-assessed using an intention-to-treat (ITT) analysis and a prespecified per-protocol (PP) analysis of patients who continued their assigned treatment. Secondary outcomes included event-free survival in both ITT and PP analyses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among the 100 original trial participants (48 in myPACE and 52 in usual care), the ITT analysis demonstrated a trend toward slower event accrual with the myPACE intervention (15 vs 33 events; Lin-Wei-Ying-Yang estimate [LWYY], 0.48; 95% CI, 0.22-1.06; P&#x2009;=&#x2009;.07) and longer event-free survival (hazard ratio [HR], 0.63; 95% CI, 0.31-1.29; P&#x2009;=&#x2009;.20) but did not reach statistical significance. In the prespecified PP analysis, 87 remained on their assigned heart rate setting over the 4-year follow-up (39 in myPACE and 48 in usual care). The mean (SD) age was 74 (10) years, and 48 participants (55%) were male. In this PP analysis, myPACE was associated with a slower accrual of clinical events (5 vs 31 events; LWYY, 0.16; 95% CI, 0.04-0.67; P&#x2009;=&#x2009;.01) and longer event-free survival (HR, 0.30; 95% CI, 0.11-0.80; P&#x2009;=&#x2009;.02) compared to usual care. These results were primarily driven by heart failure-related events.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="UNASSIGNED">In this observational clinical events analysis of the myPACE trial, analysis by ITT did not achieve statistical significance between study arms. However, PP analysis showed that personalized accelerated physiologic pacing was associated with a slower accrual of adverse clinical events compared with the standard 60-bpm setting. These results are hypothesis generating and warrant confirmation in larger multicenter trials.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="UNASSIGNED">ClinicalTrials.gov Identifier: NCT04721314.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Infeld</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiovascular Center, Tufts Medical Center, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cyr</LastName><ForeName>Jamie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Vermont Larner College of Medicine, Burlington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novelli</LastName><ForeName>Alexandra E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Medicine, Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rawlings</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Vermont Larner College of Medicine, Burlington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahlberg</LastName><ForeName>Kramer</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Vermont Larner College of Medicine, Burlington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Plante</LastName><ForeName>Timothy B</ForeName><Initials>TB</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Vermont Larner College of Medicine, Burlington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Lavallaz</LastName><ForeName>Jeanne du Fay</ForeName><Initials>JDF</Initials><AffiliationInfo><Affiliation>Department of Cardiology, University of Michigan, Ann Arbor.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Habel</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Vermont Larner College of Medicine, Burlington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lustgarten</LastName><ForeName>Daniel L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Vermont Larner College of Medicine, Burlington.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Vermont Larner College of Medicine, Burlington.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lillehei Heart Institute, Department of Medicine, University of Minnesota College of Medicine, Minneapolis.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04721314</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Cardiol</MedlineTA><NlmUniqueID>101676033</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Infeld reported compensation for lectures given at courses sponsored by Medtronic and Boston Scientific. Dr Habel reported grants from Medtronic outside the submitted work. Dr Meyer reported licensing fees from Medtronic Patent outside the submitted work; in addition, Dr Meyer had a patent for Medtronic licensed to Markus Meyer University of Vermont. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>8</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>29</Day><Hour>8</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>29</Day><Hour>8</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>27</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40864451</ArticleId><ArticleId IdType="pmc">PMC12392142</ArticleId><ArticleId IdType="doi">10.1001/jamacardio.2025.2827</ArticleId><ArticleId IdType="pii">2838117</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Infeld M, Wahlberg K, Cicero J, et al. Personalized pacing for heart failure with preserved ejection fraction&#x2014;the myPACE randomized clinical trial. JAMA Cardiol. 2023;8(3):213-221. doi: 10.1001/jamacardio.2022.5320</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2022.5320</ArticleId><ArticleId IdType="pmc">PMC9996402</ArticleId><ArticleId IdType="pubmed">36723919</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung MK, Patton KK, Lau CP, et al. 2023 HRS/APHRS/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm. 2023;20(9):e17-e91. doi: 10.1016/j.hrthm.2023.03.1538</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2023.03.1538</ArticleId><ArticleId IdType="pmc">PMC11062890</ArticleId><ArticleId IdType="pubmed">37283271</ArticleId></ArticleIdList></Reference><Reference><Citation>Infeld M, Cyr JA, S&#xe1;nchez-Quintana D, et al. Physiological pacing for the prevention and treatment of heart failure: a state-of-the-art review. J Card Fail. 2024;30(12):1614-1628. doi: 10.1016/j.cardfail.2024.08.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2024.08.063</ArticleId><ArticleId IdType="pubmed">39481799</ArticleId></ArticleIdList></Reference><Reference><Citation>Infeld M, Avram R, Wahlberg K, et al. An approach towards individualized lower rate settings for pacemakers. Heart Rhythm O2. 2020;1(5):390-393. doi: 10.1016/j.hroo.2020.09.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hroo.2020.09.004</ArticleId><ArticleId IdType="pmc">PMC7889012</ArticleId><ArticleId IdType="pubmed">33604585</ArticleId></ArticleIdList></Reference><Reference><Citation>Infeld M, Wahlberg K, Cicero J, et al. Personalized pacing for diastolic dysfunction and heart failure with preserved ejection fraction: design and rationale for the myPACE randomized controlled trial. Heart Rhythm O2. 2021;3(1):109-116. doi: 10.1016/j.hroo.2021.11.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hroo.2021.11.015</ArticleId><ArticleId IdType="pmc">PMC8859799</ArticleId><ArticleId IdType="pubmed">35243443</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L, Lin DY. Semiparametric regression for the weighted composite endpoint of recurrent and terminal events. Biostatistics. 2016;17(2):390-403. doi: 10.1093/biostatistics/kxv050</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/biostatistics/kxv050</ArticleId><ArticleId IdType="pmc">PMC4804115</ArticleId><ArticleId IdType="pubmed">26668069</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiou SH, Xu G, Yan J, Huang CY. Regression modeling for recurrent events possibly with an informative terminal event using R package reReg. J Stat Softw. 2023;105(5):1-34. doi: 10.18637/jss.v105.i05</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v105.i05</ArticleId><ArticleId IdType="pmc">PMC10997344</ArticleId><ArticleId IdType="pubmed">38586564</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman DN, Rambod M, Lustgarten DL, Lobel R, LeWinter MM, Meyer M. Heart rate-induced myocardial Ca<sup>2+</sup> retention and left ventricular volume loss in patients with heart failure with preserved ejection fraction. J Am Heart Assoc. 2020;9(17):e017215. doi: 10.1161/JAHA.120.017215
</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.120.017215</ArticleId><ArticleId IdType="pmc">PMC7660766</ArticleId><ArticleId IdType="pubmed">32856526</ArticleId></ArticleIdList></Reference><Reference><Citation>Infeld M. Accelerated physiologic pacing in patients with heart failure with preserved ejection fraction: an argument in support of therapeutic heart rate modulation. Heart Rhythm O2. 2024;5(5):327-333. doi: 10.1016/j.hroo.2024.03.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hroo.2024.03.009</ArticleId><ArticleId IdType="pmc">PMC11148487</ArticleId><ArticleId IdType="pubmed">38840759</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlberg KJ, Infeld M, Plante TB, et al. Effects of continuous accelerated pacing on cardiac structure and function in patients with heart failure with preserved ejection fraction: insights from the myPACE randomized clinical trial. J Am Heart Assoc. 2024;13(1):e032873. doi: 10.1161/JAHA.123.032873</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/JAHA.123.032873</ArticleId><ArticleId IdType="pmc">PMC10863817</ArticleId><ArticleId IdType="pubmed">38156545</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein FJ, Bell S, Runte KE, et al. Heart rate-induced modifications of concentric left ventricular hypertrophy: exploration of a novel therapeutic concept. Am J Physiol Heart Circ Physiol. 2016;311(4):H1031-H1039. doi: 10.1152/ajpheart.00301.2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00301.2016</ArticleId><ArticleId IdType="pmc">PMC5114468</ArticleId><ArticleId IdType="pubmed">27591220</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy YNV, Koepp KE, Carter R, et al. Rate-adaptive atrial pacing for heart failure with preserved ejection fraction: the RAPID-HF randomized clinical trial. JAMA. 2023;329(10):801-809. doi: 10.1001/jama.2023.0675</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.0675</ArticleId><ArticleId IdType="pmc">PMC9986839</ArticleId><ArticleId IdType="pubmed">36871285</ArticleId></ArticleIdList></Reference><Reference><Citation>Infeld M, Habel N, Wahlberg K, Meagher S, Meyer M, Lustgarten D. Bachmann bundle potential during atrial lead placement: a case series. Heart Rhythm. 2022;19(3):490-494. doi: 10.1016/j.hrthm.2021.11.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2021.11.015</ArticleId><ArticleId IdType="pmc">PMC9135382</ArticleId><ArticleId IdType="pubmed">34775070</ArticleId></ArticleIdList></Reference><Reference><Citation>Infeld M, Nicoli CD, Meagher S, et al. Clinical impact of Bachmann&#x2019;s bundle pacing defined by electrocardiographic criteria on atrial arrhythmia outcomes. Europace. 2022;24(9):1460-1468. doi: 10.1093/europace/euac029</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euac029</ArticleId><ArticleId IdType="pubmed">35304608</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>